Cohera Medical, a maker of absorbable surgical adhesives and sealants, has announced closing the first tranche of $50 million in equity financing led by KKR. Existing investors also participated in the investment. The company will use the financing to launch U.S. commercial sales of its synthetic surgical adhesive, TissuGlu, which has been approved by the U.S. Food and Drug Administration. Cohera also intends to advance clinical trials for its surgical sealant product Sylys. Ali Satvat, a director on KKR's healthcare investing team, will join Cohera’s Board.